Market Overview
The global gene panel market size was valued at USD 1,153.2 Million in 2024 and is projected to reach USD 3,775.0 Million by 2033, growing at a CAGR of 14.08% during the forecast period of 2025-2033. North America leads the market with over 36.9% share, driven by advanced healthcare infrastructure, genomic research, and extensive use of next-generation sequencing technologies. The market’s growth is supported by advancements in precision medicine, the rising prevalence of genetic disorders, and expanding applications in oncology and rare disease research.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
Gene Panel Market Key Takeaways
- The global gene panel market size was USD 1,153.2 Million in 2024.
- The market is projected to grow at a CAGR of 14.08% from 2025 to 2033.
- The forecast period for the market spans from 2025 to 2033.
- North America dominates the market with over 36.9% share in 2024, supported by its healthcare infrastructure and genomic research investment.
- The United States accounts for 75.9% of North America’s market share, boosted by precision medicine adoption and genetic disorder prevalence.
- Academic and research institutes lead the end-user segment with 42.8% market share due to significant genetic research focus.
- Test kits represent the largest product segment with around 60.5% share in 2024, driven by ease of use and clinical diagnostics adoption.
Sample Request Link: https://www.imarcgroup.com/gene-panel-market/requestsample
Market Growth Factors
The global gene panel market is expected to grow from the rise of precision medicine, genetic disorders and cancer increase, demand grows for targeted genetic testing for personalized therapeutics, and personalized cancer treatments increase through gene panels that provide accurate treatment outcomes from identification of actionable biomarkers.
Other factors fuel increased gene panel testing use with the wide use of next-generation sequencing (NGS) technologies, the decrease in genetic testing cost, the improved testing accuracy and efficiency, and gene panels that one can easily offer in the clinical setting. Insurance coverage and regulatory policies may need addressing to ensure gene panel testing use in the clinical setting.
The increasing application of gene panels for pre-gestational, antenatal, and neonatal genetic screening, as well as government-initiated national screening programs, is driving their market adoption. Their increasing reliability and feasibility for research and clinical applications is mainly attributed to their non-intrusive nature and continuous technological advances to genomic instruments.
Market Segmentation
By Products and Services:
- Test Kits: Constituting approximately 60.5% of the 2024 market, test kits are favored for their accuracy, standardized solutions, and ease of integration into clinical workflows, supporting early detection and personalized medicine.
- Testing Services
By Technique:
- Amplicon-based Approach: Leading with about 79.2% market share in 2024, this method offers cost-effectiveness, high efficiency, and simplified sample preparation, suitable for targeted sequencing in oncology and genetic disease research.
- Hybridization-based Approach
By Design:
- Predesigned Gene Panel: Dominating with around 66.5% share, these panels are cost-effective, standardized for common genetic testing, and widely adopted in diagnostics and research.
- Customized Gene Panel
By Application:
- Cancer Risk Assessment: The largest segment at approximately 54.7%, driven by rising cancer prevalence and demand for early detection to facilitate personalized treatment planning.
- Diagnosis of Congenital Diseases
- Pharmacogenetics
- Others
By End User:
- Academic and Research Institutes: Leading with 42.8% share, these institutes focus on genetic research, biomarker discovery, and therapy development supported by strong funding and collaborations.
- Hospital and Diagnostic Laboratories
- Pharmaceutical and Biotechnology Companies
Regional Insights
North America dominates the gene panel market with over 36.9% share in 2024. Its leadership stems from advanced healthcare infrastructure, high genomic research investment, and extensive use of next-generation sequencing technologies. The United States holds 75.9% of North America’s market share, driven by precision medicine adoption, regulatory support, reimbursement policies, and growing consumer awareness surrounding genetic testing.
Recent Developments & News
- February 2024: Roche Diagnostics unveiled an enhanced hereditary cancer gene panel with over 100 genes linked to diverse cancer syndromes, featuring improved variant interpretation for personalized assessments.
- April 2024: Twist Bioscience launched a service for designing and ordering customized gene panels rapidly using proprietary DNA synthesis technology.
- December 2023: Qiagen introduced a gene panel focused on neurological diseases like Alzheimer’s, Parkinson’s, and ALS to advance research and treatment development.
- April 2023: Agilent Technologies launched an NGS assay for somatic variant profiling supporting precision oncology and comprehensive genomic profiling.
- May 2023: Unipath Specialty Laboratory (India) introduced the HRD Gene Panel powered by SOPHiA GENETICS technology to identify homologous recombination deficiencies crucial for cancer treatment planning.
Key Players
- Agilent Technologies Inc.
- BGI Genomics Co. Ltd. (BGI Group)
- Eurofins Scientific SE
- F. Hoffmann-La Roche AG
- Genewiz LLC (Azenta Inc.)
- Illumina Inc.
- Integrated DNA Technologies Inc. (Danaher Corporation)
- Novogene Co. Ltd.
- Qiagen N.V.
- Thermo Fisher Scientific Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request For Customization: https://www.imarcgroup.com/request?type=report&id=8105&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
